Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer
- 1 December 2002
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (23), 4567-4573
- https://doi.org/10.1200/jco.2002.03.061
Abstract
PURPOSE: Identifying pretreatment and posttreatment predictors of time to prostate cancer–specific death (PCSD) after external-beam radiation therapy (RT) was the subject of this study. PATIENTS AND METHODS: A Cox regression analysis was used to evaluate the ability of the pretreatment risk group to predict time to PCSD for 381 patients who underwent RT for clinically localized prostate cancer. Posttreatment factors analyzed for the 94 patients who experienced prostate-specific antigen (PSA) failure included the time to PSA failure, the posttreatment PSA doubling time (DT), and the timing of salvage hormonal therapy. RESULTS: Despite the median age of 73 years at diagnosis, 45% of patients with high-risk disease were estimated to die from prostate cancer within 10 years after RT compared with 0% (P = .004) and 6% (P = .05) for patients with low- or intermediate-risk disease, respectively. Predictors of time to PCSD after PSA failure included PSA DT (P = .01) and delayed use of hormonal therapy (P ≤ .002). Nearly identical estimates of PCSD and all-cause death after PSA failure were noted for patients with a short PSA DT (ie, ≤ 12 months). CONCLUSION: Prostate cancer was a major cause of death during the first decade after RT for patients with clinically localized but high-risk disease, and the cause of death for patients with a short PSA DT after RT was nearly always prostate cancer. These data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD. Prospective validation is needed.Keywords
This publication has 20 references indexed in Scilit:
- TRANSVAGINAL ULTRASOUND OF URETHRAL SPHINCTER AT THE MID URETHRA IN CONTINENT AND INCONTINENT WOMENJournal of Urology, 2001
- Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1999
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trialThe Lancet, 1999
- Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate CancerJAMA, 1998
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998
- A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- USING PROSTATE-SPECIFIC ANTIGEN TO ELIMINATE THE STAGING RADIONUCLIDE BONE SCANUrologic Clinics of North America, 1997
- Consensus statement: Guidelines for PSA following radiation therapy1International Journal of Radiation Oncology*Biology*Physics, 1997